Transgene Biotek [TRABI] vs Biocon [BIOCON] Detailed Stock Comparison
Transgene Biotek
BSE
Loading...
Biocon
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Transgene Biotek wins in 4 metrics, Biocon wins in 14 metrics, with 0 ties. Biocon appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Transgene Biotek | Biocon | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -48.67 | 111.60 | Transgene Biotek |
| Price-to-Book Ratio | 3.04 | 1.98 | Biocon |
| Debt-to-Equity Ratio | 144.77 | 66.26 | Biocon |
| PEG Ratio | 0.16 | -1.17 | Biocon |
| EV/EBITDA | -47.44 | 19.72 | Transgene Biotek |
| Profit Margin (TTM) | 100.00% | 2.44% | Transgene Biotek |
| Operating Margin (TTM) | -380.20% | 7.46% | Biocon |
| EBITDA Margin (TTM) | N/A | 7.46% | N/A |
| Return on Equity | -6.74% | 3.66% | Biocon |
| Return on Assets (TTM) | -0.47% | 1.72% | Biocon |
| Free Cash Flow (TTM) | $-5.04M | $17.18B | Biocon |
| Dividend Yield | N/A | 0.26% | N/A |
| 1-Year Return | -43.99% | -3.01% | Biocon |
| Price-to-Sales Ratio (TTM) | 116.70 | 3.03 | Biocon |
| Enterprise Value | $415.59M | $636.19B | Biocon |
| EV/Revenue Ratio | 159.23 | 4.03 | Biocon |
| Gross Profit Margin (TTM) | 100.00% | 64.06% | Transgene Biotek |
| Revenue per Share (TTM) | $0 | $131 | Biocon |
| Earnings per Share (Diluted) | $-0.18 | $3.21 | Biocon |
| Beta (Stock Volatility) | 0.80 | 0.23 | Biocon |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Transgene Biotek vs Biocon Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Transgene Biotek | -9.82% | 14.66% | -1.13% | 1.86% | 14.06% | -28.78% |
| Biocon | 3.97% | -2.70% | -2.73% | 0.48% | 6.33% | -3.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Transgene Biotek | -43.99% | 36.45% | -0.45% | 48.98% | -91.63% | -95.45% |
| Biocon | -3.01% | 24.86% | -17.21% | 386.54% | 504.38% | 823.27% |
News Based Sentiment: Transgene Biotek vs Biocon
Transgene Biotek
News based Sentiment: NEGATIVE
The initiation of insolvency proceedings is a game-changing event for Transgene Biotek Ltd., significantly increasing the risk for investors. Coupled with consistent losses and a declining market cap, the company faces a very uncertain future, making this a critical month for its investment story.
Biocon
News based Sentiment: POSITIVE
September was a strong month for Biocon, highlighted by key FDA approvals for its biosimilars, which are expected to drive future revenue growth. While the company's valuation is high, the positive analyst ratings and strategic developments suggest continued potential. The FDA observations, while requiring monitoring, are not expected to disrupt supply.
Performance & Financial Health Analysis: Transgene Biotek vs Biocon
| Metric | TRABI | BIOCON |
|---|---|---|
| Market Information | ||
| Market Cap | ₹335.38M | ₹480.91B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 95,533 | 1,831,797 |
| 90 Day Avg. Volume | 53,167 | 2,584,107 |
| Last Close | ₹3.95 | ₹368.40 |
| 52 Week Range | ₹3.22 - ₹7.71 | ₹291.00 - ₹406.00 |
| % from 52W High | -48.77% | -9.26% |
| All-Time High | ₹322.50 (Jan 23, 2006) | ₹487.75 (Dec 21, 2020) |
| % from All-Time High | -98.78% | -24.47% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | 0.15% |
| Quarterly Earnings Growth | 0.01% | -0.95% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.02% |
| Operating Margin (TTM) | -3.80% | 0.07% |
| Return on Equity (TTM) | -0.07% | 0.04% |
| Debt to Equity (MRQ) | 144.77 | 66.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.32 | ₹180.66 |
| Cash per Share (MRQ) | ₹0.04 | ₹38.10 |
| Operating Cash Flow (TTM) | ₹1.93M | ₹17.78B |
| Levered Free Cash Flow (TTM) | ₹-6,761,000 | ₹10.13B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.26% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Transgene Biotek vs Biocon
| Metric | TRABI | BIOCON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -48.67 | 111.60 |
| Forward P/E | N/A | 36.11 |
| PEG Ratio | 0.16 | -1.17 |
| Price to Sales (TTM) | 116.70 | 3.03 |
| Price to Book (MRQ) | 3.04 | 1.98 |
| Market Capitalization | ||
| Market Capitalization | ₹335.38M | ₹480.91B |
| Enterprise Value | ₹415.59M | ₹636.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 159.23 | 4.03 |
| Enterprise to EBITDA | -47.44 | 19.72 |
| Risk & Other Metrics | ||
| Beta | 0.80 | 0.23 |
| Book Value per Share (MRQ) | ₹1.32 | ₹180.66 |
Financial Statements Comparison: Transgene Biotek vs Biocon
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TRABI | BIOCON |
|---|---|---|
| Revenue/Sales | ₹765,000 | ₹39.10B |
| Cost of Goods Sold | ₹0 | ₹14.05B |
| Gross Profit | ₹765,000 | ₹25.05B |
| Research & Development | N/A | ₹-346.00M |
| Operating Income (EBIT) | ₹-5.66M | ₹2.94B |
| EBITDA | ₹-4.98M | ₹8.29B |
| Pre-Tax Income | ₹-7.13M | ₹969.00M |
| Income Tax | ₹0 | ₹77.00M |
| Net Income (Profit) | ₹-7.13M | ₹892.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TRABI | BIOCON |
|---|---|---|
| Cash & Equivalents | ₹2.84M | ₹32.27B |
| Total Current Assets | ₹12.64M | ₹162.86B |
| Total Current Liabilities | ₹127.38M | ₹143.34B |
| Long-Term Debt | ₹61.03M | ₹129.45B |
| Total Shareholders Equity | ₹100.30M | ₹277.13B |
| Retained Earnings | N/A | ₹189.59B |
| Property, Plant & Equipment | ₹32.85M | ₹4.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TRABI | BIOCON |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TRABI | BIOCON |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 95,533 | 1,831,797 |
| Average Daily Volume (90 Day) | 53,167 | 2,584,107 |
| Shares Outstanding | 75.77M | 1.20B |
| Float Shares | 48.28M | 524.51M |
| % Held by Insiders | 0.22% | 0.56% |
| % Held by Institutions | 0.00% | 0.24% |
Dividend Analysis & Yield Comparison: Transgene Biotek vs Biocon
| Metric | TRABI | BIOCON |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.26% |
| 3-Year Avg Annual Dividend | N/A | ₹1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.36% |
| 3-Year Total Dividends | N/A | ₹4.00 |
| Ex-Dividend Date | N/A | Jul 04, 2025 |